Abbott Gains Pain-Relief Drug In $190M Deal

By Erin Coe

Law360, New York (November 12, 2009, 5:09 PM ET) -- Looking to expand its pain treatment portfolio and boost its expertise in biologics, Abbott Laboratories has snapped up PanGenetics BV’s experimental drug for chronic pain in a deal worth up to $190 million.

Abbott Park, Ill.-based Abbott said Thursday it has agreed to acquire the global rights to PG110 from the European biotechnology firm for an upfront payment of $170 million, plus additional milestone payments of up to $20 million if the drug hits development targets.

While the biologic is still in early-stage clinical testing as...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles

Sections

Law Firms Mentioned

Companies Mentioned